Trials / Completed
CompletedNCT06278493
A Clinical Study of AL2846 Capsule Combined With Gemzar Injection in the Treatment of Advanced Pancreatic Cancer
A Phase I/IIa Clinical Trial AL2846 Capsule Combined With Gemzar Injection in the Treatment of Advanced Pancreatic Cancer.
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a clinical study to observe the tolerance and primary efficacy of AL2846 capsules combined with Gemzar injection in patients with pancreatic cancer, and to determine the recommended dosage and administration method for subsequent clinical studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AL2846 capsules | AL2846 is a multi -target receptor tyrosine kinase inhibitor. |
| DRUG | Gemzar | It is a chemotherapeutic drug. |
Timeline
- Start date
- 2018-08-23
- Primary completion
- 2021-10-25
- Completion
- 2023-05-01
- First posted
- 2024-02-26
- Last updated
- 2024-02-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06278493. Inclusion in this directory is not an endorsement.